Biogen Inc. vs Merck & Company, Inc. — Stock Comparison
Biogen Inc. (BIIB) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. narrowly edges Biogen Inc. on Q·Score (6.5 vs 6.4 out of 10), led by Growth (6.4 vs 5.3) and Valuation (7.3 vs 6.5). Biogen Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for MRK (+12.6%) than for BIIB (-1.8%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.4× debt-to-equity).
⚠ low return on equity (5%).
70% of 27 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BIIB vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.5/10 versus Biogen Inc. (BIIB) at 6.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BIIB or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.4/10 vs 5.3/10). Biogen Inc. reports revenue growth (3.4% YoY) while Merck & Company, Inc. reports (5.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BIIB or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (7.3/10 vs 6.5/10). BIIB trades at 15.4× P/E versus MRK at 15.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BIIB vs MRK?
There are 32 analysts covering BIIB with a consensus price target of $248.26, and 25 analysts covering MRK with a consensus target of $159.76. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BIIB or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (4.9/10 vs 4.7/10). Net profit margin: BIIB at 8.3%, MRK at 4.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BIIB or MRK?
Biogen Inc. (BIIB) scores higher on Financial Health (9.1/10 vs 7/10). Market beta: BIIB at 0.09, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BIIB and MRK?
Biogen Inc. (BIIB) has a market capitalisation of $37.3B, while Merck & Company, Inc. (MRK) has a market cap of $349.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BIIB or MRK pay dividends?
BIIB does not currently pay a dividend, while MRK pays a dividend yield of 2.40%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →